254 related articles for article (PubMed ID: 6770131)
41. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey).
Joó I; Stanislavskii ES
J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):417-27. PubMed ID: 6819316
[TBL] [Abstract][Full Text] [Related]
42. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine].
Schiller B; Lysakowska E; Owczarska K
Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849
[No Abstract] [Full Text] [Related]
43. Immunogenic properties of serotype strains belonging to Homma's serotype schema of Pseudomonas aeruginosa.
Shionoya H; Arai H; Ohtake S
Jpn J Exp Med; 1977 Jun; 47(3):185-94. PubMed ID: 410973
[No Abstract] [Full Text] [Related]
44. Pilin-based anti-Pseudomonas vaccines: latest developments and perspectives.
Hahn H; Lane-Bell PM; Glasier LM; Nomellini JF; Bingle WH; Paranchych W; Smit J
Behring Inst Mitt; 1997 Feb; (98):315-25. PubMed ID: 9382755
[TBL] [Abstract][Full Text] [Related]
45. Antigenic relationship between the common antigen (OEP) of Pseudomonas aeruginosa and Vibrio cholerae.
Hirao Y; Homma JY
Infect Immun; 1978 Feb; 19(2):373-7. PubMed ID: 75846
[TBL] [Abstract][Full Text] [Related]
46. Antibody titers in serum of diffuse panbronchiolitis patients administered a multicomponent Pseudomonas aeruginosa vaccine consisting of toxoids of protease, elastase and exotoxin A and a common protective antigen (OEP).
Yamamoto M; Kubota Y; Matsuura M; Homma JY
Kitasato Arch Exp Med; 1988 Sep; 61(2-3):127-35. PubMed ID: 3145352
[No Abstract] [Full Text] [Related]
47. Serologic and protective cross-reactivity of antisera to Pseudomonas aeruginosa extracellular slime glycolipoprotein.
Yushkova NA; Kholodkova EV; Korobova TS; Stanislavsky ES
Acta Microbiol Hung; 1986; 33(2):147-56. PubMed ID: 3101393
[TBL] [Abstract][Full Text] [Related]
48. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ
Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346
[TBL] [Abstract][Full Text] [Related]
49. Vaccines and immunotherapy against Pseudomonas aeruginosa.
Döring G; Pier GB
Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
[TBL] [Abstract][Full Text] [Related]
50. [Development of immunological preparations and their use for preventing and treating pyocyanic infection in burn patients].
Kolker II; Stanislavskiĭ ES; Grishina IA; Panova IuM; Krokhina MA
Probl Gematol Pereliv Krovi; 1981 Jan; 26(1):29-33. PubMed ID: 6784114
[No Abstract] [Full Text] [Related]
51. Motility, virulence, and protection with a flagella vaccine against Pseudomonas aeruginosa infection.
Montie TC; Drake D; Sellin H; Slater O; Edmonds S
Antibiot Chemother (1971); 1987; 39():233-48. PubMed ID: 3118785
[No Abstract] [Full Text] [Related]
52. [[Vaccine development for P. aeruginosa: based on antigen cloning of clinical vaccines][].
von Specht BU
Zentralbl Chir; 1999; 124(4):298-302. PubMed ID: 10355084
[TBL] [Abstract][Full Text] [Related]
53. [Preliminary studies on the preparation of vaccine against Psudomonas aeruginosa patients with burns].
Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W; Zietkiewicz W
Pol Tyg Lek; 1978 Sep; 33(39):1533-6. PubMed ID: 100771
[No Abstract] [Full Text] [Related]
54. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
Weimer ET; Ervin SE; Wozniak DJ; Mizel SB
Vaccine; 2009 Nov; 27(48):6762-9. PubMed ID: 19744586
[TBL] [Abstract][Full Text] [Related]
55. [Clinical use of a Soviet polyvalent corpuscular pyocyanic vaccine for the prevention of Pseudomonas aeruginosa infection in thermal burn victims].
Gerasimova LI; Moroz AF; Radkevich SA; Sveshnikov AI; Mizikin EV
Khirurgiia (Mosk); 1980 Nov; (11):36-41. PubMed ID: 6777578
[No Abstract] [Full Text] [Related]
56. Efficiency of Pseudomonas aeruginosa vaccines in the prevention and treatment of Pseudomonas infections in burned patients.
Ionescu A; Meitert E; Vasiliu S; Meitert T; Sima F; Savulian C; Milicescu S
Arch Roum Pathol Exp Microbiol; 1981; 40(4):323-32. PubMed ID: 6803737
[No Abstract] [Full Text] [Related]
57. Pseudomonas aeruginosa surface polysaccharide vaccines. New therapeutic approaches from basic research.
Pier GB
Antibiot Chemother (1971); 1985; 36():157-67. PubMed ID: 3923913
[TBL] [Abstract][Full Text] [Related]
58. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa.
Saha S; Takeshita F; Sasaki S; Matsuda T; Tanaka T; Tozuka M; Takase K; Matsumoto T; Okuda K; Ishii N; Yamaguchi K; Klinman DM; Xin KQ; Okuda K
Vaccine; 2006 Sep; 24(37-39):6240-9. PubMed ID: 16806598
[TBL] [Abstract][Full Text] [Related]
59. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
[TBL] [Abstract][Full Text] [Related]
60. Characteristics, isolation and role in the infectious process of Pseudomonas aeruginosa protease.
Brodinova NS; Moroz AF; Luchina TYa
J Hyg Epidemiol Microbiol Immunol; 1983; 27(1):69-76. PubMed ID: 6406591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
